Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

ClinicalTrials.gov ID: NCT02157506

Public ClinicalTrials.gov record NCT02157506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

Study identification

NCT ID
NCT02157506
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
70 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2014
Primary completion
May 30, 2015
Completion
Jul 30, 2015
Last update posted
Jul 30, 2019

2014 – 2015

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Cardioxyl Study Site Gainesville Florida 32610
Cardioxyl Study Site Jacksonville Florida 32209
Cardioxyl Study Site Jacksonville Florida 32224
Cardioxyl Study Site Macon Georgia 31201
Cardioxyl Study Site Baltimore Maryland 21201
Cardioxyl Study Site Detroit Michigan 48202
Cardioxyl Study Site Newark New Jersey 07103
Cardioxyl Study Site Chapel Hill North Carolina 27517
Cardioxyl Study Site Cincinnati Ohio 45267
Cardioxyl Study Site Columbus Ohio 43201
Cardioxyl Study Site Charleston South Carolina 29425
Cardioxyl Study Site Nashville Tennessee 37232
Cardioxyl Study Site Salt Lake City Utah 84132
Cardioxyl Study Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02157506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02157506 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →